Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEnD trial of aripiprazole + sertraline versus quetiapine for bipolar depression
ISRCTN63917405Phase 3Recruiting
- Sponsor
- Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in bipolar disorder (BD) comparing sertraline + aripiprazole with quetiapine (2 arms). Primary endpoint: Improvement in depression. Started Mar 2024; status: recruiting.
02
Drugs
aripiprazolesertralinequetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ISRCTN63917405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63917405.